Medication overuse headache in patients with primary headache disorders - Epidemiology, management and pathogenesis

被引:20
作者
Dowson, AJ
Dodick, DW
Limmroth, V
机构
[1] Kings Coll Hosp London, Kings Headache Serv, London SE5 9RS, England
[2] Mayo Clin Scottsdale, Scottsdale, AZ USA
[3] Univ Hosp Essen, Dept Neurol, Essen, Germany
关键词
D O I
10.2165/00023210-200519060-00002
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Medication overuse headache (MOH) is a common medical condition that is associated with considerable long-term morbidity and disability. Patients experiencing MOH have primary headache disorders (migraine, tension-type headache [TTH] or the combination of migraine and TTH) that change to a pattern of daily or near-daily headaches over a period of years or decades following the overuse of symptomatic headache medications. Overused drugs include analgesics, ergot alkaloids, serotonin 5-HT1B/1D receptor agonists ('triptans') and medications containing barbiturates, codeine, caffeine, tranquillisers and mixed analgesics. Affected patients usually have a long history of primary headache, overuse of medications and MOH before they consult a physician for care. Patients with MOH are usually managed in specialist centres by withdrawal of the overused drugs and treatment of withdrawal symptoms (on an inpatient or outpatient basis), headache prophylaxis and limited use of symptomatic acute medications. Most patients respond to this therapy, although the prognosis is not always good and >= 50% may lapse over an initial 5-year follow-up period. The best practical strategy at present is to prevent the overuse of drugs in the first place by patient education and formal management approaches conducted in primary care to treat the primary headache before it changes to MOH. The quality of the clinical evidence on MOH is suboptimal and further biological and clinical research is urgently required to help facilitate the management of these patients more effectively in the future.
引用
收藏
页码:483 / 497
页数:15
相关论文
共 92 条
[71]   CLASSIFICATION OF DAILY AND NEAR-DAILY HEADACHES - PROPOSED REVISIONS TO THE IHS CRITERIA [J].
SILBERSTEIN, SD ;
LIPTON, RB ;
SOLOMON, S ;
MATHEW, NT .
HEADACHE, 1994, 34 (01) :1-7
[72]   Chronic daily headache [J].
Silberstein, SD ;
Lipton, RB .
CURRENT OPINION IN NEUROLOGY, 2000, 13 (03) :277-283
[73]  
SILBERSTEIN SD, 1993, WOLFFS HEADACHE OTHE, P96
[74]   WITHDRAWAL SYNDROME AFTER THE DOUBLE-BLIND CESSATION OF CAFFEINE CONSUMPTION [J].
SILVERMAN, K ;
EVANS, SM ;
STRAIN, EC ;
GRIFFITHS, RR .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (16) :1109-1114
[75]   Low-dose tizanidine with nonsteroidal anti-inflammatory drugs for detoxification from analgesic rebound headache [J].
Smith, TR .
HEADACHE, 2002, 42 (03) :175-177
[76]   CLINICAL-FEATURES OF CHRONIC DAILY HEADACHE [J].
SOLOMON, S ;
LIPTON, RB ;
NEWMAN, LC .
HEADACHE, 1992, 32 (07) :325-329
[77]   Chronic daily headache: A scientist's perspective [J].
Srikiatkhachorn, A .
HEADACHE, 2002, 42 (06) :532-537
[78]   PREVALENCE OF MIGRAINE HEADACHE IN THE UNITED-STATES - RELATION TO AGE, INCOME, RACE, AND OTHER SOCIODEMOGRAPHIC FACTORS [J].
STEWART, WF ;
LIPTON, RB ;
CELENTANO, DD ;
REED, ML .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (01) :64-69
[79]   Twelve cases of analgesic headache [J].
Symon, DNK .
ARCHIVES OF DISEASE IN CHILDHOOD, 1998, 78 (06) :555-556
[80]   Are there predictive factors for long-term outcome after withdrawal in drug-induced chronic daily headache? [J].
Tribl, GG ;
Schnider, P ;
Wöber, C ;
Aull, S ;
Auterith, A ;
Zeiler, K ;
Wessely, P .
CEPHALALGIA, 2001, 21 (06) :691-696